Leandro C Hermida
Overview
Explore the profile of Leandro C Hermida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1382
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoang D, Dinstag G, Shulman E, Hermida L, Ben-Zvi D, Elis E, et al.
Nat Cancer
. 2024 Jul;
5(9):1305-1317.
PMID: 38961276
Advances in artificial intelligence have paved the way for leveraging hematoxylin and eosin-stained tumor slides for precision oncology. We present ENLIGHT-DeepPT, an indirect two-step approach consisting of (1) DeepPT, a...
2.
Hoang D, Dinstag G, Hermida L, Ben-Zvi D, Elis E, Caley K, et al.
Res Sq
. 2023 Oct;
PMID: 37790315
Advances in artificial intelligence have paved the way for leveraging hematoxylin and eosin (H&E)-stained tumor slides for precision oncology. We present ENLIGHT-DeepPT, an approach for predicting response to multiple targeted...
3.
Nair N, Jiang Q, Wei J, Misra V, Morrow B, Kesserwan C, et al.
Cell Rep Med
. 2023 Feb;
4(2):100938.
PMID: 36773602
Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. A better understanding of mesothelioma genomics and transcriptomics could advance therapies. Here, we present a mesothelioma cohort...
4.
Luo M, Liu Y, Hermida L, Gertz E, Zhang Z, Li Q, et al.
Cancer Cell
. 2022 Sep;
40(9):901-902.
PMID: 36099885
No abstract available.
5.
Hermida L, Gertz E, Ruppin E
Nat Commun
. 2022 May;
13(1):2896.
PMID: 35610202
Tumor gene expression is predictive of patient prognosis in some cancers. However, RNA-seq and whole genome sequencing data contain not only reads from host tumor and normal tissue, but also...
6.
Lichtenstein D, Schischlik F, Shao L, Steinberg S, Yates B, Wang H, et al.
Blood
. 2021 Sep;
138(24):2469-2484.
PMID: 34525183
Chimeric antigen receptor (CAR) T-cell toxicities resembling hemophagocytic lymphohistiocytosis (HLH) occur in a subset of patients with cytokine release syndrome (CRS). As a variant of conventional CRS, a comprehensive characterization...
7.
Wang L, Gao Y, Zhang G, Li D, Wang Z, Zhang J, et al.
Sci Transl Med
. 2020 Sep;
12(560).
PMID: 32908002
Immune checkpoint blockade (ICB) therapies are now established as first-line treatments for multiple cancers, but many patients do not derive long-term benefit from ICB. Here, we report that increased amounts...
8.
Bolouri H, Farrar J, Triche Jr T, Ries R, Lim E, Alonzo T, et al.
Nat Med
. 2019 Feb;
25(3):530.
PMID: 30705421
In the version of this article originally published, the color key in Fig. 1a was wrong. In the Cytogenetics key, the box over t(8;21) originally was green. It should have...
9.
Alexander T, Gu Z, Iacobucci I, Dickerson K, Choi J, Xu B, et al.
Nature
. 2018 Sep;
562(7727):373-379.
PMID: 30209392
Mixed phenotype acute leukaemia (MPAL) is a high-risk subtype of leukaemia with myeloid and lymphoid features, limited genetic characterization, and a lack of consensus regarding appropriate therapy. Here we show...
10.
Bolouri H, Farrar J, Triche Jr T, Ries R, Lim E, Alonzo T, et al.
Nat Med
. 2018 Apr;
24(4):526.
PMID: 29634680
This corrects the article DOI: 10.1038/nm.4439.